Retrospective comparison of mobilization methods for autologous stem cell transplantation in multiple myeloma†
Hideki Nakasone
Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Saitama
Search for more papers by this authorCorresponding Author
Yoshinobu Kanda
Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Saitama
Division of Hematology, Saitama Medical Center, Jichi Medical University, 1-847, Amanuma-cho, Omiya-ku, Saitama-shi, Saitama 330-8503, JapanSearch for more papers by this authorTomoki Ueda
Division of Hematology, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo
Search for more papers by this authorKenji Matsumoto
Department of Internal Medicine and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Kanagawa
Search for more papers by this authorNaomi Shimizu
Division of Hematology, Department of Clinical Cell Biology, Chiba University Graduate School of Medicine, Chiba, Chiba
Search for more papers by this authorJiro Minami
Division of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine, Minato-ku, Tokyo
Search for more papers by this authorRika Sakai
Department of Hematology, Yokohama City University Medical Center, Yokohama, Kanagawa
Search for more papers by this authorMaki Hagihara
Department of Hematology, Kanagawa Cancer Center, Yokohama, Kanagawa
Search for more papers by this authorAkira Yokota
Department of Internal Medicine, Chiba Aoba Municipal Hospital, Chiba, Chiba
Search for more papers by this authorKumi Oshima
Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Saitama
Search for more papers by this authorYuiko Tsukada
Division of Hematology, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo
Search for more papers by this authorTakayoshi Tachibana
Department of Internal Medicine and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Kanagawa
Search for more papers by this authorChiaki Nakaseko
Division of Hematology, Department of Clinical Cell Biology, Chiba University Graduate School of Medicine, Chiba, Chiba
Search for more papers by this authorShin Fujisawa
Department of Hematology, Yokohama City University Medical Center, Yokohama, Kanagawa
Search for more papers by this authorShingo Yano
Division of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine, Minato-ku, Tokyo
Search for more papers by this authorHiroyuki Fujita
Department of Internal Medicine and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Kanagawa
Search for more papers by this authorSatoshi Takahashi
Division of Molecular Therapy, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo
Search for more papers by this authorHeiwa Kanamori
Department of Hematology, Kanagawa Cancer Center, Yokohama, Kanagawa
Search for more papers by this authorShinichiro Okamoto
Division of Hematology, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo
Search for more papers by this authorHideki Nakasone
Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Saitama
Search for more papers by this authorCorresponding Author
Yoshinobu Kanda
Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Saitama
Division of Hematology, Saitama Medical Center, Jichi Medical University, 1-847, Amanuma-cho, Omiya-ku, Saitama-shi, Saitama 330-8503, JapanSearch for more papers by this authorTomoki Ueda
Division of Hematology, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo
Search for more papers by this authorKenji Matsumoto
Department of Internal Medicine and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Kanagawa
Search for more papers by this authorNaomi Shimizu
Division of Hematology, Department of Clinical Cell Biology, Chiba University Graduate School of Medicine, Chiba, Chiba
Search for more papers by this authorJiro Minami
Division of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine, Minato-ku, Tokyo
Search for more papers by this authorRika Sakai
Department of Hematology, Yokohama City University Medical Center, Yokohama, Kanagawa
Search for more papers by this authorMaki Hagihara
Department of Hematology, Kanagawa Cancer Center, Yokohama, Kanagawa
Search for more papers by this authorAkira Yokota
Department of Internal Medicine, Chiba Aoba Municipal Hospital, Chiba, Chiba
Search for more papers by this authorKumi Oshima
Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Saitama
Search for more papers by this authorYuiko Tsukada
Division of Hematology, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo
Search for more papers by this authorTakayoshi Tachibana
Department of Internal Medicine and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Kanagawa
Search for more papers by this authorChiaki Nakaseko
Division of Hematology, Department of Clinical Cell Biology, Chiba University Graduate School of Medicine, Chiba, Chiba
Search for more papers by this authorShin Fujisawa
Department of Hematology, Yokohama City University Medical Center, Yokohama, Kanagawa
Search for more papers by this authorShingo Yano
Division of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine, Minato-ku, Tokyo
Search for more papers by this authorHiroyuki Fujita
Department of Internal Medicine and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Kanagawa
Search for more papers by this authorSatoshi Takahashi
Division of Molecular Therapy, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo
Search for more papers by this authorHeiwa Kanamori
Department of Hematology, Kanagawa Cancer Center, Yokohama, Kanagawa
Search for more papers by this authorShinichiro Okamoto
Division of Hematology, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo
Search for more papers by this authorConflict of interest: Nothing to report.
Abstract
The combination of cyclophosphamide and granulocyte-colony stimulating factor (G-CSF) has widely been used to mobilize hematopoietic stem cells (HSCs) for autologous stem cell transplantation (ASCT) for multiple myeloma (MM). Recently, however, alternative approaches such as G-CSF alone or etoposide followed by G-CSF have been investigated. We, therefore, retrospectively analyzed the effects of these mobilization methods on collection yield and disease outcome in ASCT for MM. We reviewed 146 MM patients from whom we intended to collect stem cells. For mobilization, 67, 58, and 21 patients received cyclophosphamide and G-CSF, etoposide and G-CSF, and G-CSF alone (including nonmyelosuppressive chemotherapy followed by G-CSF), respectively. Among them, 136 achieved the target number of HSCs (at least 2 × 106/kg). Lower creatinine and higher albumin levels at diagnosis were significantly associated with successful yield. A lower number of infused HSCs, use of the etoposide for mobilization and high ISS were associated with delayed hematopoietic recovery. The mobilization methods did not significantly affect either the successful collection of more than 2 × 106 CD34-positive cells/kg or PFS after ASCT. G-CSF alone was sufficient for stem cell mobilization for a single ASCT. The optimal approach to collect HSCs in MM remains to be elucidated. Am. J. Hematol., 2010. © 2009 Wiley-Liss, Inc.
REFERENCES
- 1
Mehta J,Singhal S.
High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years.
Bone Marrow Transplant
2007;
40:
1101–1114.
10.1038/sj.bmt.1705799 Google Scholar
- 2 Pant S,Copelan EA. Hematopoietic stem cell transplantation in multiple myeloma. Biol Blood Marrow Transplant 2007; 13: 877–885.
- 3 Attal M,Harousseau JL,Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–97.
- 4 Child JA,Morgan GJ,Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883.
- 5 Palumbo A,Bringhen S,Petrucci MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: Results of a randomized controlled trial. Blood 2004; 104: 3052–3057.
- 6 Desikan KR,Barlogie B,Jagannath S, et al. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol 1998; 16: 1547–1553.
- 7 Fitoussi O,Perreau V,Boiron JM, et al. A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients. Bone Marrow Transplant 2001; 27: 837–842.
- 8 Ketterer N,Salles G,Moullet I, et al. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 1998; 103: 235–242.
- 9 Pusic I,Jiang SY,Landua S, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008; 14: 1045–1056.
- 10 Russell NH,McQuaker G,Stainer C, et al. Stem cell mobilization in lymphoproliferative diseases. Bone Marrow Transplant 1998; 22: 935–940.
- 11 Seggewiss R,Buss EC,Herrmann D, et al. Kinetics of peripheral blood stem cell mobilization following G-CSF-supported chemotherapy. Stem Cells 2003; 21: 568–574.
- 12 Dingli D,Nowakowski GS,Dispenzieri A, et al. Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. Clin Lymphoma Myeloma 2006; 6: 384–388.
- 13 Copelan EA,Ceselski SK,Ezzone SA, et al. Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease. J Clin Oncol 1997; 15: 759–765.
- 14 Kanfer EJ,McGuigan D,Samson D, et al. High-dose etoposide with granulocyte colony-stimulating factor for mobilization of peripheral blood progenitor cells: Efficacy and toxicity at three dose levels. Br J Cancer 1998; 78: 928–932.
- 15 Reiser M,Josting A,Draube A, et al. Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization. Bone Marrow Transplant 1999; 23: 1223–1228.
- 16 Bolwell BJ,Pohlman B,Rybicki L, et al. Patients mobilizing large numbers of CD34+ cells (super mobilizers) have improved survival in autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant 2007; 40: 437–441.
- 17 Chou T,Ishiguro T,Imajo K, et al. [A multicenter early phase II study of high-dose chemotherapy with autologous peripheral blood stem cell transplantation for treatment of intermediate-grade non-Hodgkin's lymphoma. Japan Blood Cell Transplantation Study Group]. Rinsho Ketsueki 1999; 40: 1058–1067.
- 18 International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749–757.
- 19 Greipp PR,San Miguel J,Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–3420.
- 20 Avet-Loiseau H,Attal M,Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: The experience of the Intergroupe Francophone du Myelome. Blood 2007; 109: 3489–3495.
- 21 Durie BG,Harousseau JL,Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–1473.
- 22 Attal M,Harousseau JL,Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495–2502.
- 23 Knop S,Gerecke C,Liebisch P, et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: A report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 2009; 113: 4137–4143.
- 24 Harousseau JL. Induction therapy in multiple myeloma. Hematology Am Soc Hematol Educ Prog 2008: 306–312.
- 25 Kumar S,Giralt S,Stadtmauer EA, et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 2009; 114: 1729–1735.
- 26 Jansen J,Thompson J,Dugan M, et al. Impaired PBPC collection in patients with myeloma after high-dose melphalan. Cytotherapy 2004; 6: 498–504.
- 27 Boccadoro M,Palumbo A,Bringhen S, et al. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica 2002; 87: 846–850.
- 28 Knudsen LM,Rasmussen T,Jensen L,Johnsen HE. Reduced bone marrow stem cell pool and progenitor mobilization in multiple myeloma after melphalan treatment. Med Oncol 1999; 16: 245–254.
- 29 Mendrone AJr,Arrais CA,Saboya R, et al. Factors affecting hematopoietic progenitor cell mobilization: An analysis of 307 patients. Transfus Apher Sci 2008; 39: 187–192.
- 30 Tricot G,Jagannath S,Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: Identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588–596.
- 31 Gertz MA,Kumar SK,Lacy MQ, et al. Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transplant 2009; 43: 619–625.
- 32
Martin A,Perez-Simon JA,Caballero MD, et al.
Effect of cumulative etoposide doses on the outcome of autologous peripheral-blood progenitor-cell transplantation for lymphoma.
Bone Marrow Transplant
2004;
33:
579–587.
10.1038/sj.bmt.1704401 Google Scholar
- 33 Barlogie B,Jagannath S,Vesole DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789–793.
- 34 Dewald GW,Kyle RA,Hicks GA,Greipp PR. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 1985; 66: 380–390.
Citing Literature
